|01:00 AM ET|
Morgan Lewis FDA and Healthcare partners Donna Lee Yesner and Stephen Ruscus will speak at the ABA's 5th Biennial Federal Drug Pricing Program, "Confronting the Complexities of the Federal Drug Pricing."
Ms. Yesner, along with fellow panelists, will speak at two presentations: "Advanced Non-FAMP Issues—Complex issues that companies currently face relating to Non-FAMP calculations and collateral impact on TRRx," and "Expanding Use of FCP in Other Pricing and Insurance Programs: What Is the Proper FCP to Use, and Why Is There Disagreement?"
Mr. Ruscus, who will Chair this program, will speak on "TAA Substantial Transformation: Is Bulk Active Pharmaceutical Ingredient (API) the Same as the Approved Product—Can Pressing a Pill Ever Be Enough?" He will also participate on the panel for "Parsing the Differences: When Confusing CMS (AMP and ASP) Terminology with VA (Non-FA MP) Can Hurt You."
October 17–18, 2011
Crystal Gateway Marriott
1700 Jefferson Davis Highway